CD274 and non-small cell lung carcinoma: For several years, ICIs were the therapy of choice for second-line treatment, with atezolizumab, pembrolizumab, and nivolumab—each a programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor—being the predominant options for patients with nonsquamous NSCLC who had been treated previously with chemotherapy.1,2,3 Given their success as second-line treatments, ICIs were subsequently used as first-line treatments with 2 strategies: ICI monotherapy and ICI in combination with chemotherapy.